| scholarly article | Q13442814 |
| P50 | author | Sebastian Funk | Q37367670 |
| Timothy J. Kidd | Q42831844 | ||
| Michael M Tunney | Q56573072 | ||
| Deirdre F Gilpin | Q60602936 | ||
| P2093 | author name string | John E Moore | |
| Damian G Downey | |||
| J Stuart Elborn | |||
| Jacqueline C Rendall | |||
| John McCaughan | |||
| B Cherie Millar | |||
| Peter H Gilligan | |||
| Patrick A Flume | |||
| Philip G Murphy | |||
| P2860 | cites work | Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections | Q26768034 |
| Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing | Q29614699 | ||
| Cystic fibrosis. | Q30251439 | ||
| Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis | Q30412485 | ||
| The changing microbial epidemiology in cystic fibrosis | Q33825634 | ||
| Impact of Pseudomonas aeruginosa genomic instability on the application of typing methods for chronic cystic fibrosis infections | Q33909400 | ||
| Pulsed field gel electrophoresis: A review of application and interpretation in the molecular epidemiology of infectious disease | Q34130232 | ||
| Decade-long bacterial community dynamics in cystic fibrosis airways | Q34209009 | ||
| Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk | Q34425805 | ||
| The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations | Q34437958 | ||
| Comparison of three molecular techniques for typing Pseudomonas aeruginosa isolates in sputum samples from patients with cystic fibrosis | Q34487493 | ||
| Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period | Q34916610 | ||
| Quantifying trends in disease impact to produce a consistent and reproducible definition of an emerging infectious disease | Q34962364 | ||
| Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor | Q35127240 | ||
| Infections in patients with cystic fibrosis: diagnostic microbiology update | Q35173126 | ||
| Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology | Q35193186 | ||
| Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. | Q35536357 | ||
| Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis | Q35602934 | ||
| Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis | Q35604702 | ||
| An epidemic of burkholderia cepacia transmitted between patients with and without cystic fibrosis | Q35885860 | ||
| Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis | Q36226940 | ||
| Nine challenges in modelling the emergence of novel pathogens | Q36468417 | ||
| Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens | Q36620854 | ||
| Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort | Q36673569 | ||
| Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009-2014. | Q36935318 | ||
| Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis | Q36968540 | ||
| Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis | Q37334924 | ||
| Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium | Q37481693 | ||
| Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. | Q37887193 | ||
| Treatment of lung infection in patients with cystic fibrosis: current and future strategies | Q38058617 | ||
| European Cystic Fibrosis Society Standards of Care: Best Practice guidelines | Q38214213 | ||
| Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis | Q39097378 | ||
| Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. | Q39131829 | ||
| Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in children with cystic fibrosis. | Q39159484 | ||
| Evaluation of quantitative PCR for early diagnosis of Pseudomonas aeruginosa infection in cystic fibrosis: a prospective cohort study | Q40429062 | ||
| Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. | Q40449041 | ||
| The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis | Q40579146 | ||
| Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis | Q40704655 | ||
| Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis | Q40940721 | ||
| Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years | Q41560657 | ||
| Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients | Q42279891 | ||
| Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial | Q43227275 | ||
| Non-invasive assessment of upper and lower airway infection and inflammation in CF patients. | Q43549706 | ||
| Nontuberculous Mycobacteria in Adult Patients with Cystic Fibrosis | Q44146527 | ||
| Increasing nontuberculous mycobacteria infection in cystic fibrosis | Q44189223 | ||
| Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. | Q44272126 | ||
| Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis | Q44324883 | ||
| Burkholderia puraquae sp. nov., a novel species of the Burkholderia cepacia complex isolated from hospital settings and agricultural soils | Q45764838 | ||
| Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough? | Q48000392 | ||
| One time quantitative PCR detection of Pseudomonas aeruginosa to discriminate intermittent from chronic infection in cystic fibrosis | Q50034216 | ||
| Establishing the diagnosis of chronic colonization with Pseudomonas aeruginosa of cystic fibrosis patients: Comparison of the European consensus criteria with genotyping of P. aeruginosa isolates. | Q52588146 | ||
| Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment. | Q52662685 | ||
| Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. | Q52858669 | ||
| Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. | Q53297625 | ||
| Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis | Q83779240 | ||
| P433 | issue | 9 | |
| P921 | main subject | cystic fibrosis | Q178194 |
| emerging pathogen | Q108429945 | ||
| P577 | publication date | 2018-08-27 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis | |
| P478 | volume | 56 |
Search more.